Wedbush Securities Inc. boosted its position in Sanofi (NYSE:SNY) by 2.9% during the second quarter, Holdings Channel reports. The firm owned 19,595 shares of the company’s stock after buying an additional 550 shares during the period. Wedbush Securities Inc.’s holdings in Sanofi were worth $939,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Guggenheim Capital LLC increased its position in Sanofi by 1.5% in the fourth quarter. Guggenheim Capital LLC now owns 21,558 shares of the company’s stock worth $872,000 after buying an additional 311 shares during the period. Capstone Asset Management Co. boosted its stake in shares of Sanofi by 6.0% in the first quarter. Capstone Asset Management Co. now owns 82,197 shares of the company’s stock worth $3,719,000 after buying an additional 4,635 shares in the last quarter. Atria Investments LLC boosted its stake in shares of Sanofi by 8.9% in the first quarter. Atria Investments LLC now owns 7,386 shares of the company’s stock worth $334,000 after buying an additional 602 shares in the last quarter. BLB&B Advisors LLC bought a new stake in shares of Sanofi during the first quarter worth approximately $202,000. Finally, Cullinan Associates Inc. boosted its stake in shares of Sanofi by 5.5% in the first quarter. Cullinan Associates Inc. now owns 64,000 shares of the company’s stock worth $2,896,000 after buying an additional 3,340 shares in the last quarter. Hedge funds and other institutional investors own 9.96% of the company’s stock.

Sanofi (NYSE:SNY) opened at 47.55 on Friday. The company has a market capitalization of $119.42 billion, a PE ratio of 11.23 and a beta of 0.88. The company has a 50-day moving average price of $47.99 and a 200 day moving average price of $46.11. Sanofi has a 52-week low of $36.81 and a 52-week high of $50.24.

Sanofi (NYSE:SNY) last announced its earnings results on Monday, July 31st. The company reported $0.74 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.74. The company had revenue of $8.66 billion during the quarter, compared to the consensus estimate of $8.71 billion. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. Sanofi’s revenue for the quarter was down 2.3% on a year-over-year basis. Equities research analysts anticipate that Sanofi will post $3.26 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This article was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/08/13/sanofi-sny-shares-bought-by-wedbush-securities-inc.html.

A number of analysts have recently commented on SNY shares. J P Morgan Chase & Co reissued a “neutral” rating on shares of Sanofi in a research report on Thursday, April 20th. Zacks Investment Research cut Sanofi from a “buy” rating to a “hold” rating in a research report on Tuesday, April 25th. TheStreet raised Sanofi from a “c+” rating to a “b-” rating in a research report on Monday, April 24th. Berenberg Bank cut Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, May 11th. Finally, BidaskClub cut Sanofi from a “buy” rating to a “hold” rating in a research report on Friday, June 9th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and five have assigned a buy rating to the company’s stock. Sanofi presently has a consensus rating of “Hold” and an average price target of $63.75.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.